spacer
home > epc > autumn 2003 > pharmacogenomics and the impact on central laboratories
PUBLICATIONS
European Pharmaceutical Contractor

Pharmacogenomics and the Impact on Central Laboratories

Fifty years on from the discovery of DNA's double-helical structure, James Watson and Francis Crick's claim that they had Òfound the secret of life' has been complemented nicely by the completion of the Human Genome Project in April 2003. The Human Genome Project began in 1990 at a time when scientists had discovered fewer than 100 disease genes. Today, more than 99 per cent of the human genome has been sequenced and over 1,400 disease genes have been identified.

Human Genome Project and Drug Development

For the drug development industry, the consequences of sequencing the human genome have not yet been fully realised. Increasingly however, over the past number of years, in order to take advantage of the information gained in the Human Genome Project, pharmaceutical and biotechnology companies are seeking to incorporate pharmacogenomic components into their clinical protocols. The term pharmacogenomics is derived from the words pharmacology and genomics, and the discipline itself is a combination of those two sciences. In relation to drug development, pharmacogenomics is concerned with the study of how an individual's genetic inheritance affects the body's response to drugs.

Pharmacogenomics holds the promise that drugs can be developed which are targeted at a specific population, improving drug safety and efficacy, unlike the current practice for drug development whereby Ôone size fits all'. This current practice has proven very successful for pharmaceutical companies and many have profited significantly from a number of blockbuster drugs. However, with productivity of pharmaceutical research and development affecting revenue growth and investor confidence, many pharmaceutical companies are now examining other options for drug development, and in this regard one key area of interest is pharmacogenomics.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michelle Lynskey, Business Development Analyst at ICON Laboratories, Europe

Michelle Lynskey is Business Development Analyst at ICON Laboratories, Europe. She holds a Degree in Biotechnology from the National University of Ireland, Galway, and a Masters in Science Communication from Dublin City University and Queen's University Belfast. Prior to joining ICON Laboratories in 2002, Michelle worked as a Biochemist in Immunology R&D for Olympus Diagnostica and as a Technologies Analyst in drug delivery for Elan Corporation.

spacer
Michelle Lynskey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm accelerates strategy to broaden service offering into commercial manufacturing

MedPharm Ltd, a leading contract provider of topical and transdermal product design and development services, has announced two new appointments to its Board to support plans to grow its commercial manufacturing services.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement